FDA clears Opus Genetics' IND for OPGx-RDH12 gene therapy for childhood blindness

The FDA cleared Opus Genetics' investigational new drug application for OPGx-RDH12, an investigational gene therapy for RDH12-associated Leber congenital amaurosis, a form of childhood blindness.

Detected & updated continuously · Source: Nebula